Medicines
Imatinib, a targeted cancer drug
Imatinib blocks the rogue protein that drives chronic myeloid leukaemia. In Brian Druker's trials almost every patient went into remission, and it was approved in 2001.
Why it matters
A fatal leukaemia became a manageable condition, and it showed drugs could be designed against a cancer's own fault.
For patients
Chronic myeloid leukaemia, deadly within a few years, became a condition treated with a daily pill.
People: Brian Druker, Nicholas Lydon, Janet Rowley